About 220 results
FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome

Apr 15th, 2019 - The FDA granted fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations. The agency also granted orphan drug designation to APR-246 (Aprea Therapeutics) for treatment of myelodysplastic syndrome.

Therapy-Related AML and MDS: Who Really Has It?

Jun 4th, 2015 - Most of our knowledge of a relationship between exposure to cancer therapy and developing acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) comes from epidemiological studies. So it is important to remember epidemiology deals with associations, not cause and effect. Also, we need to avoid the logical fallacy of post hoc ergo propter hoc (after this, therefore because of this). Spec...

Genomic profiling of AML and MDS yields prognostic clues
Neil Osterweil

Jan 9th, 2020 - ORLANDO – A genome-wide study of blood and bone marrow samples from more than 1,300 adults with myeloid disorders has both confirmed the role of known or suspected driver mutations and uncovered new associations that could inform clinical care for patients with acute myeloid leukemia and myelodysplastic syndrome. Neil Osterweil/MDedge News Dr.

Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome

Dec 22nd, 2019 - NEW YORK (Reuters Health) - A study of hematopoietic stem cell transplantation (HCT) for adults with myelodysplastic syndrome (MDS) showed that patients 65 and older had comparable outcomes to those ages 55 to 64, leading the authors to recommend that the US Centers for Medicare and Medicaid Services cover HCT. "We have demonstrated the safety of HCT in older patients," Dr. Ehab Atallah of the ...

Some MCL patients can safely stop venetoclax-ibrutinib, study suggests

Dec 14th, 2019 - Treatment status Five patients are still receiving treatment with ibrutinib and venetoclax, and one patient is receiving only venetoclax. One patient went off study treatment due to a diagnosis of myelodysplastic syndrome, but that patient’s MCL is still in CR.

Inner demons

Dec 1st, 2019 - Julia Brennan sings about inner demons. They just won’t go away and they don’t play fair with angels.

Year in Review: Acute Myeloid Leukemia

Nov 1st, 2019 - A flurry of new FDA approvals -- as well as a rejection -- topped the headlines for acute myeloid leukemia (AML) over the past year, as did research looking at novel combinations in this difficult-to-treat disease, findings on long-term outcomes being tied to treatment-related cardiac toxicity, and an accounting of solid tumor patients' heightened risk for therapy-related AML and myelodysplasti...

Treosulfan Passes Test for AML Conditioning

Oct 18th, 2019 - As a conditioning regimen before allogeneic hemopoietic stem cell transplantation (HSCT), treosulfan plus fludarabine was noninferior to a standard reduced-intensity regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients who are older or have comorbidities. A randomized, international phase III trial met its primary endpoint, showing that patients treated with treos...

Treosulfan Better Than Busulfan in Prep for HSCT

Mar 4th, 2019 - HOUSTON — Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) about to undergo allogeneic hematopoietic cell transplantation (HSCT), say German researchers reporting results from a phase 3 study. The researchers compared the effect of treosulfan/fludarabi...

AML, myeloma risk higher for breast cancer survivors
Neil Osterweil

Jan 22nd, 2019 - Breast cancer survivors should continue to be monitored for hematologic malignancies, especially acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), results of a population-based study from France suggest. Among nearly 440,000 women with an incident breast cancer diagnosis, the incidence of AML was nearly three times higher and the incidence of MDS was five times higher than that o.

Higher AML, MDS risk linked to solid tumor chemotherapy
Caleb Rans

Jan 3rd, 2019 - There is an increased risk for therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) following chemotherapy for the majority of solid tumor types, according to an analysis of cancer registry data. These findings suggest a substantial expansion in the patients at risk for tMDS/AML because, in the past, excess risks were established only after chemotherapy for cancers of t.

Elevated MDS/AML Risk Post-Chemotherapy for 22 of 23 Solid Cancers

Dec 26th, 2018 - Action Points Chemotherapy and chemoradiotherapy for 22 out of 23 solid cancers raises the risk for patients to develop treatment-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML) from 1.5- to 10-fold in contrast to the general population. Young people treated with chemotherapy for bone, soft tissue, and testis cancers are at the highest risk for the development of tMDS/AML. CM...

Immaculate Regression? Perfect Cervical Ca Test; Chemo Leukemia Risk

Dec 19th, 2018 - An 11-year-old Texas girl will have a much happier holiday season after an inoperable brain tumor diagnosed earlier this year spontaneously disappeared. (Huffington Post) A test for cervical cancer using methylation signatures was 100% accurate in a study involving 15,000 women, outperforming both Pap and DNA testing. (IFL Science) Social media, specifically Facebook, proved to be an effective ...

Increased Risk of Chemo-Associated AML for Nearly All Solid Cancers

Dec 19th, 2018 - Cancer patients treated with chemotherapy for almost every type of solid tumor were found to be at increased risk for developing therapy-related myelodysplastic syndrome or acute myeloid leukemia (MDS/AML), a population-based cohort study found. Patients receiving cytotoxic agents in the modern era for 22 of 23 different solid tumor types had anywhere from a 1.5- to 10-fold increased risk for t...

After Chemo, Risk of Tx-Related Blood Cancer Higher Than Thought

Dec 19th, 2018 - Patients treated with chemotherapy for a solid tumor are at much higher risk than was previously thought of developing a highly lethal blood cancer as a result of that treatment. A research team from the National Cancer Institute (NCI) says that the relative risk of this late effect — therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) — is exponentially higher than wa...

Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndrome
Sharon Worcester

Dec 3rd, 2018 - SAN DIEGO – A newly developed personalized model that “harnesses the power of artificial intelligence” to predict overall survival and transformation to acute myeloid leukemia (AML) in patients with myelodysplastic syndromes outperforms both the original and revised International Prognostic Scoring Systems (IPSS, IPSS-R), according to Aziz Nazha, MD. The machine learning model, which was built.

Model Improves Predictions of Myelodysplastic Syndrome Prognosis

Dec 2nd, 2018 - SAN DIEGO — Patients with myelodysplastic syndrome (MDS), which rarely causes symptoms in its early stages, may now obtain a better idea of what may lie ahead for them. A machine-learning approach that analyzes genomic and clinical data can give a personalized risk assessment for each individual. It can provide overall survival (OS) estimates at different time points and predict the risk for tr...

Durable transfusion independence in MDS with imetelstat
Neil Osterweil

Oct 1st, 2018 - AMSTERDAM – For patients with low-risk myelodysplastic syndrome (MDS) for whom erythropoietin therapy has failed, the novel telomerase inhibitor imetelstat may provide long-lasting independence from transfusion, investigators reported. Neil Osterweil/MDedge News Dr.

Post-Transplant Mutations in MDS Tied to Reduced PFS

Sep 13th, 2018 - At 30 days post-transplant, myelodysplastic syndrome (MDS) patients who still had disease-associated mutations had over three times the risk of progressive disease, an exploratory analysis found. Using bone marrow from MDS patients, risk of progression was seen in 53.1% of those with a variant allele frequency ≥0.5% in a single mutation compared with 13.0% of those who did not (conditioning reg...

MDS posttransplant gene sequencing prognostic for progression
Neil Osterweil

Sep 12th, 2018 - For patients with myelodysplastic syndrome, gene sequencing of bone marrow samples early after bone marrow transplant with curative intent may provide important prognostic information. Among 86 patients with myelodysplastic syndrome (MDS), higher maximum variant allele frequency of residual disease–associated mutations at 30 days posttransplantation was significantly associated with disease pro.